The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research ...

The blue-chip board and the startup star had been on a collision course for months. Here’s what really happened.

GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...

Shanghai China financial hub and a popular foreign investment destination is home to 998 regional headquarters of multinational companies at present ...

Healthcare infrastructure development and increased funding are likely to drive demand for pharmerging.Wilmington, Delaware, ...

Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

LONDON, UNITED KINGDOM, October 17, 2024 /EINPresswire / -- Sciensus names Christian Tucat as Chief Executive Officer Sciensus, a leading pan European, life sciences business, providing patient access ...

Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...